English
简体中文
Total: £ 56.28
Published Date: 2026-03-25 | Pages: 123 | Tables: 127 | Pharma & Healthcare
The global Nucleic Acid and Oligonucleotide Therapeutics market was valued at US$ 13380 million in 2025 and is anticipated to reach US$ 17220 million by 2032, at a CAGR of 3.7% from 2026 to 2032.
Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes.
The North American market for Nucleic Acid and Oligonucleotide Therapeutics is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Nucleic Acid and Oligonucleotide Therapeutics is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Nucleic Acid and Oligonucleotide Therapeutics in Neuromuscular Diseases is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Nucleic Acid and Oligonucleotide Therapeutics include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Nucleic Acid and Oligonucleotide Therapeutics market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Nucleic Acid and Oligonucleotide Therapeutics. The Nucleic Acid and Oligonucleotide Therapeutics market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Nucleic Acid and Oligonucleotide Therapeutics market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Nucleic Acid and Oligonucleotide Therapeutics manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
Segment by Type
Antisense Oligonucleotides (ASO)
siRNA
mRNA
Segment by Application
Neuromuscular Diseases
hATTR
COVID-19
Other
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Nucleic Acid and Oligonucleotide Therapeutics companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Antisense Oligonucleotides (ASO)
1.2.3 siRNA
1.2.4 mRNA
1.3 Market by Application
1.3.1 Global Nucleic Acid and Oligonucleotide Therapeutics Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Neuromuscular Diseases
1.3.3 hATTR
1.3.4 COVID-19
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nucleic Acid and Oligonucleotide Therapeutics Market Perspective (2021–2032)
2.2 Global Nucleic Acid and Oligonucleotide Therapeutics Growth Trends by Region
2.2.1 Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Nucleic Acid and Oligonucleotide Therapeutics Historic Market Size by Region (2021–2026)
2.2.3 Nucleic Acid and Oligonucleotide Therapeutics Forecasted Market Size by Region (2027–2032)
2.3 Nucleic Acid and Oligonucleotide Therapeutics Market Dynamics
2.3.1 Nucleic Acid and Oligonucleotide Therapeutics Industry Trends
2.3.2 Nucleic Acid and Oligonucleotide Therapeutics Market Drivers
2.3.3 Nucleic Acid and Oligonucleotide Therapeutics Market Challenges
2.3.4 Nucleic Acid and Oligonucleotide Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nucleic Acid and Oligonucleotide Therapeutics Players by Revenue
3.1.1 Global Top Nucleic Acid and Oligonucleotide Therapeutics Players by Revenue (2021–2026)
3.1.2 Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Players (2021–2026)
3.2 Global Top Nucleic Acid and Oligonucleotide Therapeutics Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Nucleic Acid and Oligonucleotide Therapeutics Revenue
3.4 Global Nucleic Acid and Oligonucleotide Therapeutics Market Concentration Ratio
3.4.1 Global Nucleic Acid and Oligonucleotide Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid and Oligonucleotide Therapeutics Revenue in 2025
3.5 Global Key Players of Nucleic Acid and Oligonucleotide Therapeutics Head Offices and Areas Served
3.6 Global Key Players of Nucleic Acid and Oligonucleotide Therapeutics, Products and Applications
3.7 Global Key Players of Nucleic Acid and Oligonucleotide Therapeutics, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Nucleic Acid and Oligonucleotide Therapeutics Breakdown Data by Type
4.1 Global Nucleic Acid and Oligonucleotide Therapeutics Historic Market Size by Type (2021–2026)
4.2 Global Nucleic Acid and Oligonucleotide Therapeutics Forecasted Market Size by Type (2027–2032)
5 Nucleic Acid and Oligonucleotide Therapeutics Breakdown Data by Application
5.1 Global Nucleic Acid and Oligonucleotide Therapeutics Historic Market Size by Application (2021–2026)
5.2 Global Nucleic Acid and Oligonucleotide Therapeutics Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Nucleic Acid and Oligonucleotide Therapeutics Market Size (2021–2032)
6.2 North America Nucleic Acid and Oligonucleotide Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2021–2026)
6.4 North America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size (2021–2032)
7.2 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2021–2026)
7.4 Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Size (2021–2032)
8.2 Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2021–2026)
8.4 Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Size (2021–2032)
9.2 Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2021–2026)
9.4 Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size (2021–2032)
10.2 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2021–2026)
10.4 Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.1.4 Sarepta Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.1.5 Sarepta Therapeutics Recent Development
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Details
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.2.4 Ionis Pharmaceuticals Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.2.5 Ionis Pharmaceuticals Recent Development
11.3 Alnylam
11.3.1 Alnylam Company Details
11.3.2 Alnylam Business Overview
11.3.3 Alnylam Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.3.4 Alnylam Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.3.5 Alnylam Recent Development
11.4 Biogen
11.4.1 Biogen Company Details
11.4.2 Biogen Business Overview
11.4.3 Biogen Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.4.4 Biogen Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.4.5 Biogen Recent Development
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Details
11.5.2 Nippon Shinyaku Business Overview
11.5.3 Nippon Shinyaku Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.5.4 Nippon Shinyaku Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.5.5 Nippon Shinyaku Recent Development
11.6 Sobi
11.6.1 Sobi Company Details
11.6.2 Sobi Business Overview
11.6.3 Sobi Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.6.4 Sobi Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.6.5 Sobi Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.7.4 Novartis Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.7.5 Novartis Recent Development
11.8 BioNTech
11.8.1 BioNTech Company Details
11.8.2 BioNTech Business Overview
11.8.3 BioNTech Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.8.4 BioNTech Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.8.5 BioNTech Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.9.4 Pfizer Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.9.5 Pfizer Recent Development
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Details
11.10.2 Moderna Therapeutics Business Overview
11.10.3 Moderna Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.10.4 Moderna Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.10.5 Moderna Therapeutics Recent Development
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Details
11.11.2 Jazz Pharmaceuticals Business Overview
11.11.3 Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.11.4 Jazz Pharmaceuticals Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.11.5 Jazz Pharmaceuticals Recent Development
11.12 CureVac
11.12.1 CureVac Company Details
11.12.2 CureVac Business Overview
11.12.3 CureVac Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.12.4 CureVac Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.12.5 CureVac Recent Development
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Details
11.13.2 Regulus Therapeutics Business Overview
11.13.3 Regulus Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.13.4 Regulus Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.13.5 Regulus Therapeutics Recent Development
11.14 ProQR
11.14.1 ProQR Company Details
11.14.2 ProQR Business Overview
11.14.3 ProQR Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.14.4 ProQR Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.14.5 ProQR Recent Development
11.15 Secarna
11.15.1 Secarna Company Details
11.15.2 Secarna Business Overview
11.15.3 Secarna Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.15.4 Secarna Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.15.5 Secarna Recent Development
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Details
11.16.2 MiNA Therapeutics Business Overview
11.16.3 MiNA Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.16.4 MiNA Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.16.5 MiNA Therapeutics Recent Development
11.17 Sylentis
11.17.1 Sylentis Company Details
11.17.2 Sylentis Business Overview
11.17.3 Sylentis Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.17.4 Sylentis Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.17.5 Sylentis Recent Development
11.18 Arrowhead
11.18.1 Arrowhead Company Details
11.18.2 Arrowhead Business Overview
11.18.3 Arrowhead Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.18.4 Arrowhead Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.18.5 Arrowhead Recent Development
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Details
11.19.2 Silence Therapeutics Business Overview
11.19.3 Silence Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.19.4 Silence Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.19.5 Silence Therapeutics Recent Development
11.20 Dicerna
11.20.1 Dicerna Company Details
11.20.2 Dicerna Business Overview
11.20.3 Dicerna Nucleic Acid and Oligonucleotide Therapeutics Introduction
11.20.4 Dicerna Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
11.20.5 Dicerna Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Antisense Oligonucleotides (ASO)
Table 3. Key Players of siRNA
Table 4. Key Players of mRNA
Table 5. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (US$ Million), 2021–2026
Table 8. Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Region (2021–2026)
Table 9. Global Nucleic Acid and Oligonucleotide Therapeutics Forecasted Market Size by Region (US$ Million), 2027–2032
Table 10. Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Region (2027–2032)
Table 11. Nucleic Acid and Oligonucleotide Therapeutics Market Trends
Table 12. Nucleic Acid and Oligonucleotide Therapeutics Market Drivers
Table 13. Nucleic Acid and Oligonucleotide Therapeutics Market Challenges
Table 14. Nucleic Acid and Oligonucleotide Therapeutics Market Restraints
Table 15. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue by Players (US$ Million), 2021–2026
Table 16. Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Players (2021–2026)
Table 17. Global Top Nucleic Acid and Oligonucleotide Therapeutics Players by Tier (Tier 1, Tier 2, and Tier 3), based on Nucleic Acid and Oligonucleotide Therapeutics Revenue, 2025
Table 18. Ranking of Global Top Nucleic Acid and Oligonucleotide Therapeutics Companies by Revenue (US$ Million) in 2025
Table 19. Global 5 Largest Players Market Share by Nucleic Acid and Oligonucleotide Therapeutics Revenue (CR5 and HHI), 2021–2026
Table 20. Global Key Players of Nucleic Acid and Oligonucleotide Therapeutics, Headquarters and Area Served
Table 21. Global Key Players of Nucleic Acid and Oligonucleotide Therapeutics, Products and Applications
Table 22. Global Key Players of Nucleic Acid and Oligonucleotide Therapeutics, Date of General Availability (GA)
Table 23. Mergers and Acquisitions, Expansion Plans
Table 24. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Type (US$ Million), 2021–2026
Table 25. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Type (2021–2026)
Table 26. Global Nucleic Acid and Oligonucleotide Therapeutics Forecasted Market Size by Type (US$ Million), 2027–2032
Table 27. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Type (2027–2032)
Table 28. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (US$ Million), 2021–2026
Table 29. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Application (2021–2026)
Table 30. Global Nucleic Acid and Oligonucleotide Therapeutics Forecasted Market Size by Application (US$ Million), 2027–2032
Table 31. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue Market Share by Application (2027–2032)
Table 32. North America Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 33. North America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2021–2026
Table 34. North America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2027–2032
Table 35. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 36. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2021–2026
Table 37. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2027–2032
Table 38. Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 39. Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (US$ Million), 2021–2026
Table 40. Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Size by Region (US$ Million), 2027–2032
Table 41. Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2021–2026
Table 43. Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2027–2032
Table 44. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2021–2026
Table 46. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2027–2032
Table 47. Sarepta Therapeutics Company Details
Table 48. Sarepta Therapeutics Business Overview
Table 49. Sarepta Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product
Table 50. Sarepta Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 51. Sarepta Therapeutics Recent Development
Table 52. Ionis Pharmaceuticals Company Details
Table 53. Ionis Pharmaceuticals Business Overview
Table 54. Ionis Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Product
Table 55. Ionis Pharmaceuticals Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 56. Ionis Pharmaceuticals Recent Development
Table 57. Alnylam Company Details
Table 58. Alnylam Business Overview
Table 59. Alnylam Nucleic Acid and Oligonucleotide Therapeutics Product
Table 60. Alnylam Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 61. Alnylam Recent Development
Table 62. Biogen Company Details
Table 63. Biogen Business Overview
Table 64. Biogen Nucleic Acid and Oligonucleotide Therapeutics Product
Table 65. Biogen Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 66. Biogen Recent Development
Table 67. Nippon Shinyaku Company Details
Table 68. Nippon Shinyaku Business Overview
Table 69. Nippon Shinyaku Nucleic Acid and Oligonucleotide Therapeutics Product
Table 70. Nippon Shinyaku Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 71. Nippon Shinyaku Recent Development
Table 72. Sobi Company Details
Table 73. Sobi Business Overview
Table 74. Sobi Nucleic Acid and Oligonucleotide Therapeutics Product
Table 75. Sobi Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 76. Sobi Recent Development
Table 77. Novartis Company Details
Table 78. Novartis Business Overview
Table 79. Novartis Nucleic Acid and Oligonucleotide Therapeutics Product
Table 80. Novartis Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 81. Novartis Recent Development
Table 82. BioNTech Company Details
Table 83. BioNTech Business Overview
Table 84. BioNTech Nucleic Acid and Oligonucleotide Therapeutics Product
Table 85. BioNTech Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 86. BioNTech Recent Development
Table 87. Pfizer Company Details
Table 88. Pfizer Business Overview
Table 89. Pfizer Nucleic Acid and Oligonucleotide Therapeutics Product
Table 90. Pfizer Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 91. Pfizer Recent Development
Table 92. Moderna Therapeutics Company Details
Table 93. Moderna Therapeutics Business Overview
Table 94. Moderna Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product
Table 95. Moderna Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 96. Moderna Therapeutics Recent Development
Table 97. Jazz Pharmaceuticals Company Details
Table 98. Jazz Pharmaceuticals Business Overview
Table 99. Jazz Pharmaceuticals Nucleic Acid and Oligonucleotide Therapeutics Product
Table 100. Jazz Pharmaceuticals Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 101. Jazz Pharmaceuticals Recent Development
Table 102. CureVac Company Details
Table 103. CureVac Business Overview
Table 104. CureVac Nucleic Acid and Oligonucleotide Therapeutics Product
Table 105. CureVac Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 106. CureVac Recent Development
Table 107. Regulus Therapeutics Company Details
Table 108. Regulus Therapeutics Business Overview
Table 109. Regulus Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product
Table 110. Regulus Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 111. Regulus Therapeutics Recent Development
Table 112. ProQR Company Details
Table 113. ProQR Business Overview
Table 114. ProQR Nucleic Acid and Oligonucleotide Therapeutics Product
Table 115. ProQR Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 116. ProQR Recent Development
Table 117. Secarna Company Details
Table 118. Secarna Business Overview
Table 119. Secarna Nucleic Acid and Oligonucleotide Therapeutics Product
Table 120. Secarna Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 121. Secarna Recent Development
Table 122. MiNA Therapeutics Company Details
Table 123. MiNA Therapeutics Business Overview
Table 124. MiNA Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product
Table 125. MiNA Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 126. MiNA Therapeutics Recent Development
Table 127. Sylentis Company Details
Table 128. Sylentis Business Overview
Table 129. Sylentis Nucleic Acid and Oligonucleotide Therapeutics Product
Table 130. Sylentis Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 131. Sylentis Recent Development
Table 132. Arrowhead Company Details
Table 133. Arrowhead Business Overview
Table 134. Arrowhead Nucleic Acid and Oligonucleotide Therapeutics Product
Table 135. Arrowhead Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 136. Arrowhead Recent Development
Table 137. Silence Therapeutics Company Details
Table 138. Silence Therapeutics Business Overview
Table 139. Silence Therapeutics Nucleic Acid and Oligonucleotide Therapeutics Product
Table 140. Silence Therapeutics Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 141. Silence Therapeutics Recent Development
Table 142. Dicerna Company Details
Table 143. Dicerna Business Overview
Table 144. Dicerna Nucleic Acid and Oligonucleotide Therapeutics Product
Table 145. Dicerna Revenue in Nucleic Acid and Oligonucleotide Therapeutics Business (US$ Million), 2021–2026
Table 146. Dicerna Recent Development
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
Table 150. Authors List of This Report
List of Figures
Figure 1. Nucleic Acid and Oligonucleotide Therapeutics Picture
Figure 2. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Type: 2025 vs 2032
Figure 4. Antisense Oligonucleotides (ASO) Features
Figure 5. siRNA Features
Figure 6. mRNA Features
Figure 7. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size by Application (US$ Million), 2021–2032
Figure 8. Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Application: 2025 vs 2032
Figure 9. Neuromuscular Diseases Case Studies
Figure 10. hATTR Case Studies
Figure 11. COVID-19 Case Studies
Figure 12. Other Case Studies
Figure 13. Nucleic Acid and Oligonucleotide Therapeutics Report Years Considered
Figure 14. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 15. Global Nucleic Acid and Oligonucleotide Therapeutics Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Region: 2025 vs 2032
Figure 17. Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Players in 2025
Figure 18. Global Nucleic Acid and Oligonucleotide Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 19. The Top 10 and 5 Players Market Share by Nucleic Acid and Oligonucleotide Therapeutics Revenue in 2025
Figure 20. North America Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. North America Nucleic Acid and Oligonucleotide Therapeutics Market Share by Country (2021–2032)
Figure 22. United States Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Canada Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Nucleic Acid and Oligonucleotide Therapeutics Market Share by Country (2021–2032)
Figure 26. Germany Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. France Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. U.K. Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Italy Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Russia Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Ireland Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Nucleic Acid and Oligonucleotide Therapeutics Market Share by Region (2021–2032)
Figure 34. China Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Japan Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. South Korea Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Southeast Asia Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. India Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Australia & New Zealand Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Nucleic Acid and Oligonucleotide Therapeutics Market Share by Country (2021–2032)
Figure 42. Mexico Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Brazil Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Nucleic Acid and Oligonucleotide Therapeutics Market Share by Country (2021–2032)
Figure 46. Israel Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Saudi Arabia Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. UAE Nucleic Acid and Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Sarepta Therapeutics Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 50. Ionis Pharmaceuticals Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 51. Alnylam Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 52. Biogen Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 53. Nippon Shinyaku Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 54. Sobi Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 55. Novartis Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 56. BioNTech Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 57. Pfizer Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 58. Moderna Therapeutics Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 59. Jazz Pharmaceuticals Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 60. CureVac Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 61. Regulus Therapeutics Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 62. ProQR Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 63. Secarna Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 64. MiNA Therapeutics Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 65. Sylentis Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 66. Arrowhead Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 67. Silence Therapeutics Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 68. Dicerna Revenue Growth Rate in Nucleic Acid and Oligonucleotide Therapeutics Business (2021–2026)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
